We present a model (Figure 2) whereby the diverse, heterogeneous tumor burden in TSC patients is dependent on when first- and second-hit mutations in TSC1 or TSC2 occur during development and into adulthood. This evidence concerns the gene TSC2 and tuberous sclerosis.